Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Moderately to Severely Active Ulcerative Colitis: later-stage trial registry
2 of 3 indexed Moderately to Severely Active Ulcerative Colitis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Moderately to Severely Active Ulcerative Colitis: 3 US clinical trials tracked, 2 recruiting.
Moderately to Severely Active Ulcerative Colitis is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 3 of these trials.
Enrollment posture brief
Registry condition moderately-to-severely-active-ulcerative-colitis
OPEN 2 | RECR 67% | LATE 3 | EARLY 0 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Moderately to Severely Active Ulcerative Colitis lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Moderately to Severely Active Ulcerative Colitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Moderately to Severely Active Ulcerative Colitis is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
NCT06588855
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
NCT07158242
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
NCT06589986
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Moderately to Severely Active Ulcerative Colitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Moderately to Severely Active Ulcerative Colitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Moderately to Severely Active Ulcerative Colitis page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Moderately to Severely Active Ulcerative Colitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Moderately to Severely Active Ulcerative Colitis trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Moderately to Severely Active Ulcerative Colitis condition card totals 3 registered trials; most-linked intervention Afimkibart; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.